The hallucinogenic effect of bromo-DragonFLY is mediated by its agonist activity at the 5-HT2A serotonin receptor. Bromo-DragonFLY also has a high binding affinity for the 5-HT2B and 5-HT2C serotonin receptors, and is most accurately described as a non-subtype selective 5-HT2 agonist, as it is actually twice as potent an agonist for 5-HT2C receptors as for 5-HT2A, as well as being less than 5x selective for 5-HT2A over 5-HT2B.
It is further suggested that Bromo-DragonFLY almost completely inhibits MAO-A activity, which makes itself unable to metabolize. This is probably the cause for an abnormal duration of action.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Compared to LSD, this compound presents a significantly less pronounced body high, reduced visual effects and more in-depth hallucinations which are comparable to mescaline or 2C-B. Despite the visual and physical effects, it reportedly tends to maintain a level of sober thought structure. As the user usually retains acute cognitive sobriety, Bromo-DragonFLY can be considered to have diminished effects of confusion and potential delusions when compared to 4-AcO-DMT, psilocin, or LSD.
Bromo-DragonFLY can be considered extremely toxic at very high dosages with several deaths and numerous hospitalizations reported on overdoses. It can also have vasoconstrictive effects]], which can result in severe tissue damage or even limb amputation. Due to its high potency,one can easily overdose if this substance is not measured correctly ("eyeballed") or mislabeled as another substance.
The toxicity and long-term health effects of recreational Bromo-toxic dose is unknown. This is because Bromo-DragonFLY is a research chemical with very little history of human usage.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
On May 7, 2011, in the United States, two young adults died and several others were hospitalized after overdosing on Bromo-DragonFLY, which they believed was 2C-E.
Bromo-not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of Bromo-almost immediately after ingestion. After that,614 days to be back at baseline (in the absence of further consumption). Bromo-DragonFLY presents cross-tolerance with Cross-all psychedelics, meaning that after the consumption of Bromo-DragonFLY all psychedelics will have a reduced effect.
The risk of Bromo-DragonFLY overdose is unknown at the time, suggesting that there may not be a safe dosage. Non-oral routes also seem to exhibit a higher chance of overdosing, perhaps owing to differences in bioavailability, potency and unpredictability of dosage and effects. Overdose effects of typically include bizarre, delusional and sometimes violent behavior, amnesia, numbness, confusion and anxiety. The user may not be able to communicate and can be severely agitated. At appropriately high doses, more severe side effects include panic attacks, seizures, dangerously prolonged elevated heart rate, blood pressure and vasoconstriction. Vasoconstriction typically develops to its peak several hours into the intoxication and will need medical assistance since Bromo-DragonFLY is known to do this for an extremely long time.
The abnormally long duration of Bromo-DragonFLY poses a significant risk by staying inside the body for weeks.
In the event of an overdose, benzodiazepines can be administered to mitigate the hyper-agitative effects. A potent vasodilator will need to be continuously administered to prevent a hypertensive emergency, necrosis, organ failure and death from the resulting hypoxia. As a result, emergency medical services should always be sought in the event of an overdose.
Australia:** Bromo-DragonFLY is nationally a Schedule 9 substance, making it illegal to possess, produce and sell.
Canada:** Bromo-DragonFLY was listed as a Schedule III Substance as of October 12, 2016, along several other research chemicals.
Denmark:** Possession, production and sale is illegal.
Finland:** Possession, production and sale is illegal.
Germany:** Bromo-DragonFLY is controlled under the NpSG, as it is a derivative of 2-Phenethylamine. Production and sale is illegal. Possession and import, although illegal, is not penalized if intended for self-consumption.
Japan: Bromo-DragonFLY is a controlled substance in Japan effective August 19th, 2015.
Norway:** Bromo-DragonFLY is considered a narcotic in Norway.
Romania:** Possession, production and sale is illegal.
Sweden:** Bromo-DragonFLY is listed as a Schedule IV substance, making it illegal to possess, produce and sell.
Switzerland: Bromo-DragonFLY is likely illegal in Switzerland. It is unclear whether Bromo-DragonFLY is in the scope of a substituted a-methylphenethylamine under Verzeichnis E point 130, since it is not an "alkyl, alkoxy, alkylenedioxy or halide derivative of phenethylamine", while additionally containing further univalent substituents, according to the scope. It is also unclear if it can be considered a true ether analog of an ether analog of DOB, which would make it controlled under Buchstabe C. It could be considered an ether analog of an ether analog of para-bromoamphetamine, which would also make it illegal under Buchstabe C, but the extent of all these definitions are unknown.
Turkey:** Bromo-DragonFLY is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - It is illegal to produce, supply, or import this substance under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
United States:** Bromo-DragonFLY is listed as a Schedule I substance in Oklahoma.The Oklahoman, "https://www.oklahoman.com/story/news/crime/2012/08/13/man-sentenced-in-2011-designer-drug-deaths-of-two-oklahoma-college-students/61052749007/ Man sentenced in 2011 designer drug deaths of two Oklahoma college students"
Responsible use
Volumetric dosing
Research chemicals
Substituted phenethylamines
DOx
2C-B-FLY
Bromo-DragonFLY (Wikipedia)
Bromo-DragonFLY (Erowid Vault)
Bromo-DragonFLY (Isomer Design)
Bromo-DragonFLY (Drugs-Forum)
Bromo-DragonFLY can be administered via oral. The route of administration can influence both the onset and intensity of olfactory hallucination.